<DOC>
	<DOCNO>NCT01855789</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , parallel group study evaluate impact MTX discontinuation efficacy subcutaneous tocilizumab ( RoActemra/Actemra ) participant moderate severe active rheumatoid arthritis inadequate response current MTX therapy . Participants initiate tocilizumab 162 milligram ( mg ) weekly every 2 week , remain stable dose MTX . At Week 24 , participant achieve DAS28 le equal ( &lt; /= ) 3.2 randomize either continue receive stable dose MTX switch match placebo Week 52 . In magnetic resonance imaging ( MRI ) substudy participant treatment arm ( MTX placebo ) , MRI image hand wrist obtain analyze .</brief_summary>
	<brief_title>A Study Impact Methotrexate ( MTX ) Discontinuation Efficacy Subcutaneous Tocilizumab With Methotrexate Participants With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Body weight &lt; /=150 kilogram ( kg ) Active moderate severe rheumatoid arthritis ( DAS28 great equal [ &gt; /= ] 4.4 ) accord revised 1987 American College Rheumatology ( ACR ) criteria screen baseline ( prior treatment Day 1 ) Currently receive oral MTX least 24 week stable oral dose least 15 mg/week least 6 week prior treatment ( Day 1 ) , follow exception : stable dose least 10 mg/week allow participant body weight less ( &lt; ) 50 kg calculate glomerular filtration rate ( creatinine clearance ) &lt; 60 milliliter per minute ( mL/min ) History parenteral ( subcutaneous intramuscular ) MTX allow , within 6 week prior treatment ( Day 1 ) . Participants must document , clinically significant intolerance oral MTX must receive oral MTX dose 15 mg/week least 6 week prior treatment ( Day 1 ) Prior enrollment , discontinue etanercept &gt; /=2 week , infliximab , certolizumab , adalimumab , golimumab &gt; /=8 week Oral corticosteroid must &lt; /=10 mg/day prednisone ( equivalent ) stable least 25 28 day prior treatment ( Day 1 ) Participants receive treatment outpatient basis Documented medical history significant intolerance oral MTX &gt; /=15 mg/week Participants receive ( nonMTX ) disease modify antirheumatic drug ( DMARDs ) within 8 week screen Previous treatment abatacept , rituximab , tofacitinib , anakinra Treatment intrarticular parenteral corticosteroid within 4 week prior treatment Previous treatment celldepleting therapy alkylating agent Previous treatment tocilizumab Major surgery ( include joint surgery ) within 8 week prior screen plan surgery within 12 month follow randomization Rheumatic autoimmune disease rheumatoid arthritis Nonrheumatic autoimmune disease ( e.g . inflammatory bowel disease , psoriasis , multiple sclerosis ) Prior history current inflammatory joint disease rheumatoid arthritis Functional Class IV accord revise ( 1987 ) ACR criterion rheumatoid arthritis History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Evidence significant uncontrolled concomitant disease ; uncontrolled disease state flare commonly treated oral parenteral corticosteroid Active current history recurrent infection , major episode infection require hospitalization treatment intravenous antibiotic within 4 week prior screen oral antibiotic within 2 week prior screen Active tuberculosis require treatment within previous 3 year History currently active primary secondary immunodeficiency Pregnant breastfeed woman Positive hepatitis B hepatitis C infection For potential MRI substudy participant : presence metalcontaining device object body</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>